The B2B SaaS (Business-to-Business Software as a Service) industry involves cloud-based software applications provided to other businesses, typically on a subscription model (Fuelfinance). These applications are accessed online, eliminating the need for software installations. Clients can scale their usage of the software as their business needs grow, offering flexibility to accommodate increasing customer volume and operational demands.
Market Size and Growth
The B2B SaaS market was valued at USD 327.74 billion in 2023 and is expected to reach USD 1,088.15 billion by 2030, growing at a CAGR of 18.7% during the forecast period of 2024-2030 (“B2B SaaS Market Size, Scope, Growth, Opportunities and Forecast”). This significant growth reflects the increasing demand for cloud-based solutions across various business functions, from CRM and marketing automation to project management and design tools.
Innovations and the Future of the Industry
Several key innovations are shaping the future of B2B SaaS:
- Generative AI: Companies like Canva, Adobe, Salesforce, and Monday.com are incorporating generative AI into their products to enhance customer experience and streamline operations (Hughes).
- Digital Construction: In industries like construction, SaaS is revolutionizing project management by enabling stakeholders to collaborate on digital representations of projects before physical implementation, enhancing efficiency and global collaboration (Loring).
- Data Security: As SaaS companies handle vast amounts of sensitive data, there is an increased focus on cybersecurity and robust data protection mechanisms to safeguard against data breaches (Mandelecha).
Major Players in the B2B SaaS Market
The B2B SaaS space features a wide range of tools catering to various business needs. Key players include:
- CRM: Salesforce, Zoho CRM, Pipedrive
- Marketing Automation: HubSpot, Marketo, ActiveCampaign
- E-commerce: Shopify, BigCommerce, Magento
- Design Tools: Adobe Creative Cloud, Canva, Figma
- Email Marketing: Mailchimp, Constant Contact, Drip
- Team Communication: Slack, Microsoft Teams, Zoom
- SEO Analysis: Ahrefs, SEMrush, Moz
Competitive Landscape
Threat of New Entrants: Moderate to High
The B2B SaaS industry is highly competitive, with numerous startups entering the market regularly. The low capital requirements for developing certain software, especially in CRM and financial planning niches, lower the barriers to entry. However, higher development costs and specialized expertise are required for more complex systems like hospital management or enterprise resource planning (Yankulov and Yankulov). Despite this, economies of scale help established players manage costs, reducing the overall threat of new entrants (Serverless Makes SaaS Business Model Obsolete, and Open-source Is the New King | Webiny).
Rivalry Among Existing Competitors: Extremely High
With a large volume of companies within each niche, competition is fierce. SaaS providers face constant pressure to innovate and differentiate their offerings to capture market share (Cullen). The growth rate for the industry is slowing, with the average rate dropping from 11% to 8% annually, increasing the intensity of competition (Average SaaS Growth Rate in 2024: Brief Guide for Startups). Customers can easily switch between service providers, making it challenging for companies to retain their market position (“How Does This Work With SaaS and B2b Customers”).
Supplier Power: Moderate to High
B2B SaaS companies rely on cloud computing providers for infrastructure support, such as AWS, Microsoft Azure, and Google Cloud (Thomas). While there are numerous suppliers in the market, these large cloud providers wield significant power due to their scalability and dominance, giving them the ability to increase prices without significant loss of customers. Additionally, SaaS companies often integrate tools from other providers, such as HubSpot or Salesforce, further solidifying the dependence on a few key suppliers (Vitulli).
Buyer Power: High
Given that B2B SaaS companies typically operate on a subscription model with smaller recurring payments, buyers have significant power (SubscriptionFlow). They can easily switch between service providers unless deeply integrated into a specific system. However, SaaS companies often offer long-term value and implement value-based pricing, which helps reduce churn and makes it harder for buyers to switch purely based on pricing fluctuations.
Threat of Substitutes: High
The abundance of similar software solutions within each SaaS niche increases the threat of substitutes. Customers can easily switch between providers offering comparable features and pricing models, with relatively low switching costs, which intensifies competitive pressure (Vitulli).
Conclusion
The B2B SaaS industry is experiencing rapid growth, driven by innovations like AI integration and the shift toward digital solutions in various sectors. However, competition is fierce, and companies must continue to innovate to stay relevant. Despite the challenges of differentiation and the constant threat of new entrants, the ongoing shift toward cloud-based solutions and the demand for scalable, secure software ensures the industry’s continued expansion in the coming years.
Promising B2B SaaS Startups in North Carolina
North Carolina is home to several promising B2B SaaS startups that show strong potential for growth and innovation in the tech space. These companies have garnered attention due to their unique value propositions, growing revenue trajectories, and strong management teams. Below is an analysis of three such companies: Pendo, upSWOT, and Automation Intellect.
Pendo
Pendo is a product experience platform designed to help businesses improve their user experiences. The platform offers a suite of tools, including in-app guidance, product analytics, and user feedback, enabling businesses to better understand user behavior, optimize product adoption, and increase retention (Pendo).
Unique Value Proposition (UVP)
Pendo’s competitive edge lies in its all-in-one platform, which delivers deep insights based on trillions of user interactions. This vast dataset empowers product teams to improve user experiences and foster both growth and retention.
Financial Performance
Pendo has demonstrated strong revenue growth, with $144.4 million in revenue for 2022, up from $100 million in 2021 and $62 million in 2020 (Pendo, “Pendo Surpasses $200 Million in ARR, Releases Record Number of New Products During Fiscal Year | Pendo.io”). As of 2024, the company’s annual recurring revenue (ARR) exceeds $200 million, marking a significant jump from $100 million in 2021.
- Total Funding: $356 million (Pendo, “Pendo Raises $150 Million to Help Companies Deliver Software That Meets Rising User Expectations | Pendo.io”)
- Valuation: $2.6 billion
- Series: F Round
Founders and Management
Pendo was founded by Todd Olson (CEO), Erik Troan (CTO), and Rahul Jain (Product & Corporate Development), a team with extensive expertise in software product development, marketing, and engineering.
- Todd Olson, the CEO, graduated from Carnegie Mellon University with a degree in Computer Science (Olson). Before founding Pendo, he launched another company and gained significant experience in software product development and marketing through various roles.
- Erik Troan, the CTO, holds an engineering degree from North Carolina State University (Erik Troan – Raleigh-Durham-Chapel Hill Area | Professional Profile | LinkedIn). He previously founded multiple companies and has served in both director and consulting positions.
- Rahul Jain, leading Product and Corporate Development, earned his undergraduate degree in Software Engineering from Georgia Tech and an MBA from the University of Maryland (Rahul Jain – Washington, District of Columbia, United States | Professional Profile | LinkedIn). His professional background includes valuable experience in software engineering and product development.
- Pendo’s leadership team also includes roles such as CFO, CMO, Chief Product Officer, Chief People Officer, Chief Revenue Officer (CRO), and a dedicated Head of Engineering, collectively driving the company’s continued expansion and innovation.
upSWOT
upSWOT is a data analytics platform tailored to financial institutions, particularly banks, and their small and medium-sized business (SMB) clients (Perishable). The platform integrates various SaaS applications used by these businesses, providing valuable insights for better decision-making and financial management.
Unique Value Proposition (UVP)
upSWOT aims to empower SMBs to thrive by providing comprehensive business management and embedded finance tools. Their platform offers financial institutions the ability to help their clients make informed business decisions, increase resilience, and drive financial success.
Financial Performance
upSWOT’s estimated revenue is $16.4 million, reflecting the growth of its platform among financial institutions and SMBs (Growjo).
- Total Funding: $5.1 million
Founders and Management
The company was founded by Dmitry Norenko, a seasoned entrepreneur with extensive experience in leading tech ventures (Dmitry Norenko – Graphio.ai | LinkedIn). The management team is strong, with expertise in quality assurance, business analytics, product management, and customer support, essential for ensuring the platform’s ongoing success and scalability.
Automation Intellect
Automation Intellect is an asset performance management platform for manufacturers (Automation Intellect). Using industrial Internet of Things (IIoT), cloud computing, and advanced analytics, the platform provides real-time visibility into machine performance, helping companies optimize production, reduce downtime, and enhance product quality.
Unique Value Proposition (UVP)
The platform offers quick implementation—delivering ROI within weeks rather than years—by providing manufacturers with actionable insights to improve asset performance and increase operational efficiency. This makes it particularly attractive for companies looking to enhance their manufacturing processes without long delays.
Financial Performance
Automation Intellect has seen steady revenue growth, reaching $2.6 million in 2024. The company has a valuation of $17.6 million, using an ERP revenue multiple of 6.6x (Bailyn).
- Total Funding: $6.6 million
- Latest Funding Round: $1.7 million (2024)
Founders and Management
Automation Intellect was founded by Roger Costa and Brad DeMarco, and has an advisory board of people with experience in manufacturing analytics.
- Roger Costa (CEO) brings strong leadership and business management experience from his time at Duke and previous roles in consulting and executive leadership (“Roger Costa Profile”).
- Brad DeMarco (Chairman and Co-founder) provides engineering expertise, having previously founded other businesses and held management roles (DeMarco). Their combined experience strengthens Automation Intellect’s positioning in the competitive manufacturing tech space.
Investment Potential and VC Considerations
Each of these companies presents strong investment potential due to their innovative products, growing revenue, and experienced management teams. Let’s explore the specific strengths that make them attractive to venture capital firms:
- Pendo stands out due to its all-in-one product experience platform, broad dataset, and robust growth trajectory, making it a prime candidate for continued expansion in the product experience and user engagement markets.
- upSWOT offers a niche yet highly relevant solution in the financial services sector, specifically focused on providing SMBs with business management and embedded finance tools. This positions it well in an underserved market with a high demand for digital transformation in financial services.
- Automation Intellect benefits from its focus on manufacturing optimization, a sector increasingly looking for data-driven solutions. The quick ROI and real-time visibility it offers are highly attractive to manufacturers seeking to optimize productivity and asset performance.
All three companies are poised for continued growth, backed by strong leadership and expanding market opportunities. Given their solid financial performance and unique value propositions, they represent strong candidates for venture capital investment, particularly within the tech sector.
Biotech Industry
The biotechnology industry is a science-driven sector that utilizes living organisms, molecular biology, and biochemistry to develop healthcare-related products, including drugs, therapies, and diagnostic tools (Kagan). The industry is instrumental in the development of treatments for various diseases and disorders, ranging from common ailments to rare conditions. Biotechnology also plays a key role in other sectors such as agriculture, environmental management, and industrial processes.
Revenue Models in Biotechnology
Biotech companies typically adopt the following revenue models:
- Tech Partnering: Involves licensing or revenue-sharing agreements where biotech firms receive a share of any deals or sales made by their clients (Contributor).
- Asset Creation and Out-licensing: This model focuses on creating intellectual property (IP) assets, such as new drug candidates, and licensing or selling them to larger pharmaceutical companies.
Given the high cost of research and development (R&D), biotech companies face challenges scaling rapidly. However, technological advancements in biomanufacturing and partnerships with established pharmaceutical companies can facilitate growth.
Market Size and Growth
The global biotechnology market was valued at USD 1.08 trillion in 2023 and is projected to grow at a CAGR of 13.96% from 2024 to 2030, reaching USD 2.27 trillion by the end of the forecast period (Biotechnology Market Size, Share and Trend Analysis by Technology (Nanobiotechnology, DNA Sequencing, Cell-based Assays), by Application (Health, Bioinformatics), by Region, and Segment Forecasts, 2024 – 2030). This growth is driven by continued advancements in genetic therapies, personalized medicine, and an expanding portfolio of biotechnology products.
Future Trends in the Biotech Industry
Several key innovations are shaping the future of biotechnology:
- Gene Therapy: The development of gene therapies to treat genetic disorders and chronic conditions is an exciting frontier for biotech companies. This technology promises to deliver long-term cures rather than symptom management (Life Sciences – Our Latest Thinking).
- mRNA Vaccine Development: Following the success of COVID-19 vaccines, mRNA technology is being explored for other infectious diseases, such as the flu and HIV, offering the potential for rapid, scalable vaccine development.
- Monoclonal Antibody Development: The growth of monoclonal antibody therapies for cancer, autoimmune diseases, and other conditions is another key area of innovation.
Major Players in the B2B SaaS Market
- Animal Biotechnology: Includes animal health, veterinary vaccines, and genetically modified animals for research purposes.
- Medical Biotechnology: Focuses on drug development, gene therapy, vaccines, and diagnostics.
- Industrial Biotechnology: Involves the use of biotech processes in manufacturing, including biofuels and biodegradable plastics.
- Environmental Biotechnology: Uses microorganisms and other biotech methods to address environmental challenges, such as pollution control and waste management.
- Plant Biotechnology: Includes genetically modified crops, agricultural bio-products, and related innovations to improve food security.
Key players driving advancements across these sectors include Novo Nordisk, Regeneron Pharmaceuticals, Vertex Pharmaceuticals, Moderna, Beigene, BioNTech SE, Genmab, Biomarin Pharmaceuticals, Alnylam Pharmaceuticals, and Argenx, each excelling in diverse therapeutic areas and pushing the boundaries of biotechnology.
Competitive Landscape
Competitive Rivalry: High
The biotech industry is highly competitive, with numerous companies developing products in overlapping therapeutic areas (RBC Capital Markets | Pathfinders in Biopharma Podcast). Innovation is key, and companies often hold patents for their novel discoveries. However, the industry faces lower exit barriers because companies can sell their intellectual property to larger players (Why Patents Matter in Biotechnology | George Washington University). This intense competition is compounded by the high cost of R&D and regulatory hurdles.
Threat of New Entrants: Low to Moderate
Entering the biotech sector requires substantial investment in research and development (R&D), clinical trials, and infrastructure. The reliance on FDA approval adds further complexity, as the process is time-consuming and expensive, with uncertain outcomes (FDA). Additionally, legal liabilities surrounding drug safety and efficacy can pose significant risks for new companies. Producers typically manufacture large quantities of small products, such as specific drugs or therapies. Established firms have the necessary infrastructure, expertise, and distribution networks to handle these complex processes, creating a high barrier for new companies trying to produce similar products (Team). New entrants often lack the manufacturing scale and established channels required to compete effectively. Success in biotech depends heavily on product differentiation, effective marketing, and brand name recognition.
Supplier Power: Low
Most suppliers of the biotech industry provide commodity products like chemicals and manufacturing equipment, which biotech firms can easily switch between. High-tech suppliers, such as those providing lab equipment, also have limited influence due to the high capital requirements to enter the field. Therefore, they are forced to supply large quantities at relatively low prices (“In-Depth Industry Outlook: Commodity Chemicals Market Size, Forecast”). Biotech companies are typically more focused on their own innovations than on supplier relationships.
Customer Power: Low
Customer power in the biotech industry is relatively low for patients, as they do not have direct influence over drug pricing (Whiteside). Physicians prescribing biotech drugs typically do not benefit financially from the sale of these medications. However, insurance companies and pharmacies hold more power, as they can refuse to cover certain treatments or negotiate for better pricing, especially once patents on drugs expire. Yet, even pharmacies don’t have power over newer drug firms that are still under patent or have very few manufacturers. Plus, pharmacies don’t have an incentive to provide the lowest pricing to patients as their profit margins rise when patients pay more.
Threat of Substitutes: Moderate
For drugs treating common diseases, the expiration of patents allows generic drugs to enter the market, providing a cheaper alternative. However, for rare diseases or drugs with strong IP protection, the threat of substitutes is lower. Monoclonal antibodies and gene therapies are often difficult to replicate, providing protection from substitutes for many biotech firms (Adamkasi).
Conclusion
The biotechnology industry is poised for significant growth, driven by advancements in gene therapy, mRNA vaccine development, and monoclonal antibody therapies. While the industry faces challenges such as high R&D costs, regulatory hurdles, and intense competition, the increasing demand for innovative treatments offers ample opportunities for growth. Biotech companies continue to leverage their IP and technological partnerships to expand their reach and improve healthcare outcomes worldwide.
Promising Biotech Startups in North Carolina
Here are three promising biotech startups based in North Carolina, each with innovative technologies and strategies poised for success in the healthcare sector. These companies leverage cutting-edge science and a deep understanding of medical needs to create disruptive products, making them attractive candidates for venture capital firms in the biotech industry. Below is an analysis of the three: Oncurie, Parion Sciences, and BioAesthetics
Oncurie
Oncurie is advancing the development of a new generation of radiopharmaceuticals, specifically targeting the treatment of ovarian cancer (“Oncurie”). The company is researching new periodic elements as radioisotopes and has discovered a compound capable of effectively delivering radioisotopes directly to ovarian cancer cells, showing promise in targeted therapies.
Unique Value Proposition (UVP)
Oncurie’s innovative approach to radiopharma, utilizing unique radioisotope compounds for cancer treatment, represents a significant breakthrough in oncology. By improving the targeting of cancerous cells, Oncurie aims to enhance the precision and efficacy of cancer treatments while minimizing side effects.
Financial Performance
Oncurie has secured grants from the STTR and Small Business Research programs for further development (Oncurie Secures STTR Grant to Advance Targeted Treatment for Ovarian Cancer | North Carolina Biotechnology Center). Similar products in the field have generated between $500 million to $1 billion in revenue, highlighting Oncurie’s potential market impact (RePORT ⟩ RePORTER).
Founders and Management
Oncurie was founded by Jonathan Lindsey and has an advisory board of people with experience in radiopharma.
- Jonathan Lindsey, Founder and President, holds a PhD in Chemistry from North Carolina State University and has extensive experience in radiopharma (“Jonathan Lindsey”). He previously founded multiple startups and runs a lab where Oncurie’s groundbreaking radionuclide carrier was developed.
- Suzanne Lapi, Scientific Advisory Board Chair and Research Collaborator, is a leading expert in radiopharma from the University of Alabama, contributing significant clinical testing expertise (“Suzzane Lapi Profile”).
Parion Sciences
Parion Sciences is a development-stage biotech company focusing on treating respiratory diseases and disorders related to compromised mucosal surface defenses (Parion Sciences). The company’s core technology centers around epithelial sodium channel (ENaC) blockers, which help restore the natural mucosal defenses of the lungs and improve conditions like cystic fibrosis and dry eye disease.
Unique Value Proposition (UVP)
Parion’s proprietary ENaC blockers target diseases caused by deficiencies in the body’s natural mucosal defenses, offering potential treatments for a wide range of underserved respiratory conditions. Their focus on epithelial biology allows the company to explore new mechanisms and therapeutic indications, expanding the possibilities for innovative treatments. Parion has the potential to disrupt the market in diseases like cystic fibrosis and dry eye, areas with significant unmet medical needs. The company’s partnerships and research suggest it could make substantial inroads in the therapeutic space.
Financial Performance
- Revenue: $5.3 million (“Parion Sciences Inc”)
- Funding: < $5 million
- Valuation: Based on a median revenue multiple of 12.97, Parion is valued at approximately $68.74 million.
- Secured grant funding from the National Institutes of Health (NIH) and the Cystic Fibrosis Foundation Therapeutics.
- Granted worldwide commercialization rights for its dry eye disease treatment to Shire, valued at $535 million (Life Science Success Stories in North Carolina | NC Bio).
Founders and Management
Parion Sciences was founded by Paul Boucher and has a leadership team with experience in respiratory diseases and mucosal surface defenses.
- Paul Boucher, CEO and President, holds an MBA from Kenan-Flagler Business School and has a strong background in corporate leadership, including strategic development and negotiations, gained from roles at Toyota (“Paul Boucher Profile”).
BioAesthetics
BioAesthetics is developing a tissue-engineered nipple-areolar complex (NAC) graft for breast cancer patients who have undergone mastectomies (“Coming Soon – BioAesthetics”). The NAC graft is designed to be a customizable, off-the-shelf product that helps reconstruct the nipple-areolar complex during breast reconstruction surgery. The graft serves as a scaffold that encourages the body to regenerate its own tissue, providing a more natural reconstruction outcome.
Unique Value Proposition (UVP)
BioAesthetics offers a highly innovative approach to breast cancer reconstruction, combining tissue engineering with regenerative medicine. Their NAC graft is designed to enhance the aesthetic and functional outcomes of breast cancer reconstruction, making the process less invasive and more effective compared to traditional techniques.
Financial Performance
- Total Funding: $7.35 million (BioAesthetics Stock Price, Funding, Valuation, Revenue and Financial Statements)
- The company has received support from the North Carolina Biotech Center and is currently in the pre-clinical phase of development.
- BioAesthetics holds three patents on polymer-permeated grafts, positioning itself as a leader in the field of regenerative breast reconstruction.
Founders and Management
BioAesthetics was founded by Juliana Blum. Its management team has expertise in tissue engineering and reconstruction for breast cancer patients.
- Juliana Blum, Founder and CEO, holds a PhD in Molecular Biology from Loyola University and has a background in biotechnology entrepreneurship (“Juliana Blum Profile”). She is also an Entrepreneur-in-Residence at the North Carolina Biotech Center, providing BioAesthetics access to critical startup resources.
Conclusion
These three biotech startups—Oncurie, Parion Sciences, and BioAesthetics—represent significant innovation in healthcare, each addressing critical areas with high growth potential. From targeted cancer therapies using radiopharmaceuticals to breakthroughs in respiratory treatments and breast cancer reconstruction, these companies have distinct unique value propositions (UVPs) and strong leadership teams. Given the increasing demand for specialized, personalized medicine and advancements in regenerative technologies, these companies are well-positioned to attract venture capital investment, particularly as they continue to push the boundaries of what is possible in their respective fields.
References
Adamkasi. “Porter Five Forces Analysis of US Pharmaceutical Industry – Porter Analysis.” Porter Analysis, 14 June 2017, www.porteranalysis.com/porter-five-forces-analysis-of-us-pharmaceutical-industry/#:~:text=If%20the%20drug%20is%20still,is%20from%20low%20to%20medium.
Automation Intellect. “Analytics Software to Improve Your Bottom Line | Automation Intellect.” Automation Intellect | Analytics Software to Improve Your Bottom Line, 13 Nov. 2024, www.automationintellect.com.
Average SaaS Growth Rate in 2024: Brief Guide for Startups. 9 Dec. 2024, www.eleken.co/blog-posts/average-saas-growth-rate-brief-guide-for-startups#:~:text=The%20average%20SaaS%20growth%20rate,a%208%25%20CAGR%20throughout%202024.
“B2B SaaS Market Size, Scope, Growth, Opportunities and Forecast.” Verified Market Research, 22 Jan. 2024, www.verifiedmarketresearch.com/product/b2b-saas-market/#:~:text=B2B%20SaaS%20Market%20Size%20And,the%20forecast%20period%202024%2D2030.
Bailyn, Evan. “SaaS Valuation Multiples: 2024 Report.” First Page Sage, 11 Dec. 2024, firstpagesage.com/business/saas-valuation-multiples.
BioAesthetics Stock Price, Funding, Valuation, Revenue and Financial Statements. www.cbinsights.com/company/bioaesthetics/financials.
Biotechnology Market Size, Share and Trend Analysis by Technology (Nanobiotechnology, DNA Sequencing, Cell-based Assays), by Application (Health, Bioinformatics), by Region, and Segment Forecasts, 2024 – 2030. www.grandviewresearch.com/industry-analysis/biotechnology-market#:~:text=Biotechnology%20Market%20Size%20%26%20Trends,13.96%25%20from%202024%20to%202030.
“Coming Soon – BioAesthetics.” BioAesthetics, 5 Sept. 2024, bio-aesthetics.com.
Contributor, External. “Everything You Need to Know About Biotech Business Models.” Labiotech.eu, 17 Feb. 2023, www.labiotech.eu/expert-advice/biotech-business-models.
Cullen, Mike. Why Your SaaS Start-Up Will Probably Fail. 6 Feb. 2021, www.linkedin.com/pulse/why-your-saas-start-up-probably-fail-michael-cullen#:~:text=is%20relatively%20low.-,Bargaining%20Power%20of%20Buyers,buyer%20power%20is%20very%20high.
DeMarco, Brad. Downtime Is Costing You $100k per Hour! 24 Aug. 2018, www.linkedin.com/in/braddemarcodds.
Dmitry Norenko – Graphio.ai | LinkedIn. 10 May 2016, www.linkedin.com/in/norenkodmitry.
Erik Troan – Raleigh-Durham-Chapel Hill Area | Professional Profile | LinkedIn. www.linkedin.com/in/eriktroan.
FDA. “FDA’s Regulation of Plant And Animal Biotechnology Products.” US Food and Drug Administration, 12 Dec. 2024, www.fda.gov/safety/fdas-regulation-plant-and-animal-biotechnology-products.
Fuelfinance. “Fuelfinance – Financial Modeling for Startups – Fuel Finance.” Fuel Finance, 22 Apr. 2024, www.googleadservices.com/pagead/aclk?sa=L&ai=DChcSEwiOrN7K6suKAxU7SUcBHeDTJrwYABACGgJxdQ&co=1&ase=2&gclid=Cj0KCQiA4L67BhDUARIsADWrl7EB4B_OTeW1WV9QaXhmK9eKkDLX0YafAEMleczYsqZvjRz9UwL5khsaAnCaEALw_wcB&ohost=www.google.com&cid=CAESVuD2ac-l0yI8dnOsXBw9MULRFfDF-yDwbBgrcYVIrQ_zlXxJzsJ58TTLlPLAUMZb0ALtiFJAd8dZYelwyZOIj2PKcC4dx4TMViuCUcjcNdVOYRVBiznb&sig=AOD64_1T8ceGceiRhgTcQ97OL5Xp9Mm4Ig&q&nis=4&adurl&ved=2ahUKEwiuq9nK6suKAxVwLVkFHcf6Bi0Q0Qx6BAgGEAE.
Growjo. UpSwot: Revenue, Competitors, Alternatives. growjo.com/company/UpSwot.
“How Does This Work With SaaS and B2b Customers.” You Exec, youexec.com/questions/how-does-this-work-with-saas-and-b2b-customers#:~:text=The%20bargaining%20power%20of%20suppliers,and%20high%20threat%20of%20substitution.
Hughes, Owen. “8 Top Generative AI Companies: Innovation Giants.” eWEEK, 16 Dec. 2024, www.eweek.com/artificial-intelligence/generative-ai-companies.
“In-Depth Industry Outlook: Commodity Chemicals Market Size, Forecast.” Verified Market Research, 21 Apr. 2024, www.verifiedmarketresearch.com/product/commodity-chemicals-market/#:~:text=Commodity%20Chemicals%20Market%20Size%20And,%2C%20and%20chlorine%2C%20among%20others.
“Jonathan Lindsey.” Department of Chemistry, chemistry.sciences.ncsu.edu/people/jslindse.
“Juliana Blum Profile.” LinkedIn, www.linkedin.com/in/juliana-blum-a03925. Accessed 31 Dec. 2024.
Kagan, Julia. “Biotechnology.” Investopedia, 3 Aug. 2023, www.investopedia.com/terms/b/biotechnology.asp#:~:text=Investopedia%20%2F%20Theresa%20Chiechi-,What%20Is%20Biotechnology%3F,(such%20as%20DNA%20fingerprinting).
Life Science Success Stories in North Carolina | NC Bio. www.ncbiotech.org/success.
Loring, Jon. “What Is Digital Construction? 7 Best Practices.” Hitachi Solutions, 2 Apr. 2024, global.hitachi-solutions.com/blog/digital-construction.
Mandelecha, Aatish. “STRAC.” Guide to SaaS Data Protection: User Data Security in SaaS Applications, 6 Sept. 2024, www.strac.io/blog/saas-data-protection-user-data-security-in-saas-applications#:~:text=Key%20strategies%20for%20securing%20user,insider%20threats%2C%20and%20insecure%20APIs.
Olson, Todd. Why The Cloud 100 Matters. 25 Oct. 2018, www.linkedin.com/in/toddaolson.
“Oncurie.” Oncurie, www.oncurie.com.
Oncurie Secures STTR Grant to Advance Targeted Treatment for Ovarian Cancer | North Carolina Biotechnology Center. 17 Dec. 2024, www.ncbiotech.org/news/oncurie-secures-sttr-grant-advance-targeted-treatment-ovarian-cancer.
Parion Sciences. www.parion.com.
“Parion Sciences Inc.” ZoomInfo, www.zoominfo.com/c/parion-sciences-inc/111675848.
“Paul Boucher Profile.” LinkedIn, www.linkedin.com/in/paul-boucher-996b377. Accessed 31 Dec. 2024.
Pendo. “Pendo Raises $150 Million to Help Companies Deliver Software That Meets Rising User Expectations | Pendo.io.” Pendo.io, 10 July 2023, www.pendo.io/news/pendo-raises-150-million-to-help-companies-deliver-software-that-meets-rising-user-expectations.
—. “Pendo Surpasses $200 Million in ARR, Releases Record Number of New Products During Fiscal Year | Pendo.io.” Pendo.io, 6 Mar. 2024, www.pendo.io/news/pendo-surpasses-200-million-in-arr-releases-record-number-of-new-products-during-fiscal-year.
—. “Pendo.io – Product Experience and Digital Adoption Solutions.” Pendo.io, 4 Dec. 2024, www.pendo.io.
Perishable. “upswot.com.” Copyright prelive.upswot.com – All Rights Reserved., www.upswot.com.
Rahul Jain – Washington, District of Columbia, United States | Professional Profile | LinkedIn. www.linkedin.com/in/rahuljain4.
RBC Capital Markets | Pathfinders in Biopharma Podcast. www.rbccm.com/en/gib/biopharma/episode/balancing-act-biotech-juggles-innovation-competition-policy-and-funding#:~:text=Innovation%2C%20however%2C%20is%20a%20double,revenue%20share%20and%20slow%20development.
RePORT ⟩ RePORTER. reporter.nih.gov/project-details/10918937#description.
“Roger Costa Profile.” LinkedIn, www.linkedin.com/in/rogercosta. Accessed 31 Dec. 2024.
Serverless Makes SaaS Business Model Obsolete, and Open-source Is the New King | Webiny. www.webiny.com/blog/serverless-makes-saas-obsolete.
SubscriptionFlow. “A Comprehensive Guide to B2B SaaS Pricing Models.” SubscriptionFlow, 2 Dec. 2024, www.subscriptionflow.com/2023/09/comprehensive-guide-to-b2b-saas-pricing-models/#:~:text=What%20are%20B2B%20SaaS%20Pricing,types%20of%20pricing%20models%20operate.
“Suzzane Lapi Profile.” LinkedIn, www.linkedin.com/in/suzannelapi. Accessed 31 Dec. 2024.
Team, Investopedia. “What Are Barriers to Entry for Pharma Companies?” Investopedia, 28 Nov. 2024, www.investopedia.com/ask/answers/052215/what-are-major-barriers-entry-new-companies-drugs-sector.asp.
Thomas, Mike. “42 SaaS in Cloud Computing Companies to Know.” Built In, 20 Nov. 2024, builtin.com/articles/saas-in-cloud-computing#:~:text=Slack.%20What%20it%20does:%20Slack%20offers%20cloud%2Dbased,share%20screens%20and%20communicate%20via%20mobile%20app.
Vitulli, Franz. “Master B2B/SaaS Product Strategy With Porter’s Five Forces.” Franz Vitulli, 4 Sept. 2024, franzvitulli.com/b2b-saas-product-strategy-porters-five-forces.
Whiteside, Eric. “The Industry Handbook: Pharma Industry.” Investopedia, 31 Jan. 2022, www.investopedia.com/articles/markets/051316/industry-handbook-pharma-industry.asp.
Why Patents Matter in Biotechnology | George Washington University. healthcaremba.gwu.edu/blog/why-patents-matter-in-biotech. Yankulov, Kalo, and Kalo Yankulov. “What Is B2B SaaS: All the Basics You Need to Know.” Encharge, 18 Nov. 2024, encharge.io/what-is-b2b-saas/#:~:text=SaaS%20businesses%20tend%20to%20operate,70%25%20and%20above%20profit%20margins.